Bao Pharma repurchases 110,900 H-shares; treasury stock climbs to 1.37 million

Bulletin Express07-22

Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) reported the repurchase of 110,900 H-shares on 22 July 2026 via on-market transactions on the Hong Kong Stock Exchange. The buyback was executed at prices ranging from HKD 17.63 to HKD 18.39, with a volume-weighted average cost of HKD 17.99 per share, bringing the total cash outlay to HKD 1.99 million.

Prior to the transaction, the company had 153.07 million issued shares (excluding treasury shares) and 1.26 million treasury shares. Following the repurchase, the issued share count declined by 0.07% to 152.96 million, while treasury shares increased to 1.37 million. Total shares outstanding, including treasury stock, remained unchanged at 154.33 million because the repurchased shares have not yet been cancelled.

The 22 July purchase forms part of a broader share-buyback mandate approved on 26 May 2026, which authorises the company to repurchase up to 15.43 million shares. To date, Bao Pharma has repurchased 1.37 million shares under this mandate, utilising 8.89% of the authorised limit. Under Hong Kong listing rules, the company is now subject to a moratorium on issuing new shares or disposing of treasury shares until 21 August 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1137706624?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 18:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137706624","market":"us","top_or_hot":-1,"title":"Bao Pharma repurchases 110,900 H-shares; treasury stock climbs to 1.37 million","media":"Bulletin Express","content":"<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) reported the repurchase of 110,900 H-shares on 22 July 2026 via on-market transactions on the Hong Kong Stock Exchange. The buyback was executed at prices ranging from HKD 17.63 to HKD 18.39, with a volume-weighted average cost of HKD 17.99 per share, bringing the total cash outlay to HKD 1.99 million.</p>\n<p>Prior to the transaction, the company had 153.07 million issued shares (excluding treasury shares) and 1.26 million treasury shares. Following the repurchase, the issued share count declined by 0.07% to 152.96 million, while treasury shares increased to 1.37 million. Total shares outstanding, including treasury stock, remained unchanged at 154.33 million because the repurchased shares have not yet been cancelled.</p>\n<p>The 22 July purchase forms part of a broader share-buyback mandate approved on 26 May 2026, which authorises the company to repurchase up to 15.43 million shares. To date, Bao Pharma has repurchased 1.37 million shares under this mandate, utilising 8.89% of the authorised limit. Under Hong Kong listing rules, the company is now subject to a moratorium on issuing new shares or disposing of treasury shares until 21 August 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bao Pharma repurchases 110,900 H-shares; treasury stock climbs to 1.37 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBao Pharma repurchases 110,900 H-shares; treasury stock climbs to 1.37 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-22 18:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) reported the repurchase of 110,900 H-shares on 22 July 2026 via on-market transactions on the Hong Kong Stock Exchange. The buyback was executed at prices ranging from HKD 17.63 to HKD 18.39, with a volume-weighted average cost of HKD 17.99 per share, bringing the total cash outlay to HKD 1.99 million.</p>\n<p>Prior to the transaction, the company had 153.07 million issued shares (excluding treasury shares) and 1.26 million treasury shares. Following the repurchase, the issued share count declined by 0.07% to 152.96 million, while treasury shares increased to 1.37 million. Total shares outstanding, including treasury stock, remained unchanged at 154.33 million because the repurchased shares have not yet been cancelled.</p>\n<p>The 22 July purchase forms part of a broader share-buyback mandate approved on 26 May 2026, which authorises the company to repurchase up to 15.43 million shares. To date, Bao Pharma has repurchased 1.37 million shares under this mandate, utilising 8.89% of the authorised limit. Under Hong Kong listing rules, the company is now subject to a moratorium on issuing new shares or disposing of treasury shares until 21 August 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1137706624","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137706624","pubTimestamp":1784715661,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) reported the repurchase of 110,900 H-shares on 22 July 2026 via on-market transactions on the Hong Kong Stock Exchange. The buyback was executed at...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"宝医药回购H股11.09万股；美国国库股攀升至137万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) reported the repurchase of 110,900 H-shares on 22 July 2026 via on-market transactions on the Hong Kong Stock Exchange. The buyback was executed at prices ranging from HKD 17.63 to HKD 18.39, with a volume-weighted average cost of HKD 17.99 per share, bringing the total cash outlay to HKD 1.99 million.\nPrior to the transaction, the company had 153.07 million issued shares (excluding treasury shares) and 1.26 million treasury shares. Following the repurchase, the issued share count declined by 0.07% to 152.96 million, while treasury shares increased to 1.37 million. Total shares outstanding, including treasury stock, remained unchanged at 154.33 million because the repurchased shares have not yet been cancelled.\nThe 22 July purchase forms part of a broader share-buyback mandate approved on 26 May 2026, which authorises the company to repurchase up to 15.43 million shares. To date, Bao Pharma has repurchased 1.37 million shares under this mandate, utilising 8.89% of the authorised limit. Under Hong Kong listing rules, the company is now subject to a moratorium on issuing new shares or disposing of treasury shares until 21 August 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137706624","isCrawlerRequest":true}